Prostate cancer is a clinically heterogeneous disease and remains the most common non-
skin malignancy in men worldwide (Abate-Shen and Shen, 2000; Litwin and Tan, 2017) …

© Translational Cancer Research. All rights reserved. Transl Cancer Res 2023; 12 (1): 4-7|
https://dx. doi. org/10.21037/tcr-22-2423 multi-omic approaches to improve outcomes in …

Prostate cancer (PCa), a common malignancy in men, presents a complex and variable
disease landscape, requiring precise evaluation for personalized treatment decisions …

Simple Summary There is a tremendous amount of gene expression information available
for prostate cancer, but very few tools exist to combine the disparate datasets generated …

Cancer arises following alterations at different cellular levels, including genetic and
epigenetic modifications, transcription and translation dysregulation, as well as metabolic …

Background. Majority of prostate cancer (PCa) deaths are attributed to localized high‐grade
aggressive tumours which progress rapidly to metastatic disease. A critical unmet need in …

The non-responsiveness towards the therapy of prostate tumors is due to an extreme
genetic heterogeneity including various tumor subpopulations depending on the genetic …

Prostate cancer (PCa) is the second most common male cancer worldwide, but effective
biomarkers for the presence or progression risk of disease are currently elusive. In a series …

Background Prostate cancer (PCa) management can benefit from novel
concepts/biomarkers for reducing the current 20-30% chance of false-negative diagnosis …

Prostate cancer (PCa) is a genetically heterogeneous cancer entity that causes challenges
in pre-treatment clinical evaluation, such as the correct identification of the tumor stage …